Status:
RECRUITING
Gene Therapy(FT-003) for Wet AMD
Lead Sponsor:
Frontera Therapeutics
Collaborating Sponsors:
Tianjin Medical University Eye Hospital
The First Affiliated Hospital of Soochow University
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
50-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). Th...
Detailed Description
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals. The avail...
Eligibility Criteria
Inclusion
- Subjects that are willing and able to follow study procedures;
- Female or male patients 50-80 years old at the time of signing the ICF;
- Clinically diagnosed with nAMD;
- Presence of active CNV
- The best corrected visual acuity (BCVA) of the studied eye is 24-73 letters;
Exclusion
- •Presence of any other intraocular diseases other than nAMD in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator.
Key Trial Info
Start Date :
August 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 15 2028
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06492863
Start Date
August 15 2023
End Date
October 15 2028
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University Eye Hospital
Tianjin, Tianjin,China, China, 300392